Natera

YTD

ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).

CEO

Stephen Leonard Chapman

CEOStephen Leonard Chapman

Employees

6,140

Employees6,140

Headquarters

Austin, Texas

HeadquartersAustin, Texas

Founded

2003

Founded2003

Employees

6,140

Employees6,140

NTRA Key Statistics

Market cap

55.74B

Market cap55.74B

Price-Earnings ratio

-270.82

Price-Earnings ratio-270.82

Dividend yield

—

Dividend yield—

Average volume

1.61M

Average volume1.61M

High today

$389.00

High today$389.00

Low today

$365.20

Low today$365.20

Open price

$368.26

Open price$368.26

Volume

627.52K

Volume627.52K

52 Week high

$389.00

52 Week high$389.00

52 Week low

$157.43

52 Week low$157.43

Stock Snapshot

With a market cap of 55.74B, Natera(NTRA) trades at $386.69. The stock has a price-to-earnings ratio of -270.82.

On 2026-09-22, Natera(NTRA) stock moved within a range of $365.20 to $389.00. With shares now at $386.69, the stock is trading +5.9% above its intraday low and -0.6% below the session's peak.

Trading volume for Natera(NTRA) stock has reached 627.52K, versus its average volume of 1.61M.

Over the past 52 weeks, Natera(NTRA) stock has traded between a high of $389.00 and a low of $157.43.

NTRA News

TipRanks 4h

Natera announces Signatera receives regulatory approval in Japan

Natera (NTRA) announced that its Signatera test has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency as a companion diagnost...

Nasdaq 5h

Natera Announces Japan's PMDA Authorization For Signatera In Muscle-Invasive Bladder Cancer

(RTTNews) - Natera, Inc. (NTRA) announced that its Signatera test has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency as a...

CNBC 24h

Final Trade: Uber, Micron, Natera and Datadog - CNBC

...

Analyst ratings

85%

of 26 ratings

Buy

84.6%

Hold

15.4%

Sell

More NTRA News

Simply Wall St 1d

How Lung Cancer Data Will Impact Natera Stock Investors

Natera and collaborators recently reported four lung cancer abstracts at the IASLC 2026 World Conference on Lung Cancer, including a 1,129 patient Signatera mol...

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.